Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
Norimichi AkiyamaMasato KarayamaMoriya IwaizumiYukiko KusamaMasato KonoHironao HozumiYuzo SuzukiKazuki FuruhashiNoriyuki EnomotoTomoyuki FujisawaYutaro NakamuraNaoki InuiTakafumi Suda
Author information

2017 Volume 56 Issue 17 Pages 2367-2371


Chemotherapy for multiple primary cancers is challenging. We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. A 78-year-old woman with advanced EGFR-mutated lung adenocarcinoma was simultaneously diagnosed with duodenal adenocarcinoma. After the treatment with erlotinib, the lung cancer responded well, but her duodenal cancer showed no response. S-1 was added to erlotinib, and the duodenal cancer demonstrated a good response with tolerable toxicities. The concurrent use of erlotinib and S-1 was safe and efficacious for synchronous lung cancer harboring an EGFR mutation and duodenal cancer.

Information related to the author
© 2017 by The Japanese Society of Internal Medicine
Previous article Next article